Press Release
KYLYS AESTHETICS SA successfully completes patient injections in its first clinical trial, enrolling 55 patients with promising preliminary outcomes.
Geneva, Switzerland – February 6th, 2026 – KYLYS AESTHETICS SA, a Swiss clinical-stage biotech company developing next-generation regenerative aesthetic medical devices, today announces the successful completion of patient injections in its first clinical trial. A total of 55 patients have now been treated as part of this study evaluating the company’s proprietary hyaluronic acid-based injectable technology.
This milestone marks a significant step forward in the clinical development of KYLYS AESTHETICS’ Class III medical device. The trial is designed to assess safety, performance, and clinical behavior of the product. All planned patient injections have been completed in accordance with the approved clinical protocol.
Preliminary observations following the injections are promising, showing outcomes consistent with the company’s expectations in terms of product handling, tissue integration, and aesthetic performance. Full clinical data analysis is currently ongoing and will be completed in line with regulatory and clinical best practices.
KYLYS AESTHETICS’ technology is based on a patented hyaluronic acid platform. The company’s approach aims to go beyond traditional volumizing fillers by focusing on regenerative properties, natural integration into targeted tissues, and clinical performance.
KYLYS AESTHETICS extends its sincere thanks to the investigators, clinical sta , patients, and scientific partners who made this study possible, as well as to the Swiss innovation ecosystem supporting the company’s development.
About KYLYS AESTHETICS SA Founded in Switzerland, KYLYS AESTHETICS SA is at the forefront of regenerative aesthetic medicine. With a pipeline of advanced hyaluronic acid-based medical devices and cosmeceutical products, the company is committed to improving patient outcomes through innovation, science, and sustainability.